EnglishFollowing its creation in July 2011, the company now anounces a first round of financing of 500 000 Euros. If the conditions are filled, this first round will be completed at the begining of 2012 following conditions that were defined with the present financial partners : Cathey World Investment Ltd., and ABALIS Finances AG.
This financing will allow SurgiMab to finalize the pre-clinical development of its first conjugate targeting digestive tumors and to set up the first clinical assays that should take place within Montpellier’s Val d’Aurelle Regional Anti-Cancer Center. SurgiMAb was assisted for this operation by the Law Firm Brunswick and by Biotech Developement Conseil.